Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know
L Della Corte, V Foreste, C Di Filippo… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Poly (ADP-ribose) polymerase (PARP) inhibitors are being developed in
maintenance and recurrence treatment settings of epithelial ovarian cancers (EOCs) with …
maintenance and recurrence treatment settings of epithelial ovarian cancers (EOCs) with …
Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
N Takebe, AR Naqash, G O'Sullivan Coyne… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest,
leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid …
leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid …
PARP inhibitors and haematological malignancies—friend or foe?
KA Skelding, LF Lincz - Cancers, 2021 - mdpi.com
Simple Summary PARP inhibitors are a class of orally active drugs that kill a range of cancer
types by inducing synthetic lethality. The usefulness of PARP inhibitors for the treatment of …
types by inducing synthetic lethality. The usefulness of PARP inhibitors for the treatment of …
Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non–small cell lung cancer
R de Haan, MM van den Heuvel, J van Diessen… - Clinical Cancer …, 2021 - AACR
Purpose: To identify an MTD of olaparib, a PARP inhibitor, in combination with loco-regional
radiotherapy with/without cisplatin for the treatment of non–small cell lung cancer (NSCLC) …
radiotherapy with/without cisplatin for the treatment of non–small cell lung cancer (NSCLC) …
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
EM Stringer-Reasor, JE May, E Olariu… - Breast Cancer …, 2021 - Springer
Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved
for cancer patients with germline BRCA1/2 (g BRCA1/2) mutations, and efforts to expand the …
for cancer patients with germline BRCA1/2 (g BRCA1/2) mutations, and efforts to expand the …
SARC025 arms 1 and 2: A phase 1 study of the poly (ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing …
R Chugh, KV Ballman, LJ Helman, S Patel… - Cancer, 2021 - Wiley Online Library
Background In preclinical Ewing sarcoma (ES) models, poly (adenosine diphosphate
ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with …
ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with …
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung …
A Argiris, J Miao, MC Cristea, AM Chen, JM Sands… - Clinical lung cancer, 2021 - Elsevier
Background We conducted a 2-part study to evaluate the incorporation of veliparib, a PARP
inhibitor, into chemoradiotherapy (CRT) for stage III non–small-cell lung cancer. Patients …
inhibitor, into chemoradiotherapy (CRT) for stage III non–small-cell lung cancer. Patients …
[HTML][HTML] Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer
Objectives Veliparib is a potent poly (ADP)-ribose polymerase (PARP) 1 and 2 inhibitor that
impedes repair of DNA damage induced by cytotoxic and radiation therapies. This phase 1 …
impedes repair of DNA damage induced by cytotoxic and radiation therapies. This phase 1 …
Poly (ADP-Ribose) polymerase inhibitors for arsenic trioxide–resistant acute promyelocytic leukemia: Synergistic in vitro antitumor effects with hypomethylating agents …
M Giansanti, A De Gabrieli, SP Prete, T Ottone… - … of Pharmacology and …, 2021 - ASPET
Arsenic trioxide (ATO) is an anticancer agent used for the treatment ofacute promyelocytic
leukemia (APL). However, 5%–10% of patients fail to respond or experience disease …
leukemia (APL). However, 5%–10% of patients fail to respond or experience disease …
BRCA Mutation and PARP Inhibitors
This chapter discusses the biology of the breast cancer susceptible gene (BRCA) gene as it
pertains to its role in cancer, the effects of mutations in BRCA genes, the role of polymerase …
pertains to its role in cancer, the effects of mutations in BRCA genes, the role of polymerase …